A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

Authors

Keywords

Journal

Volume 31, Issue 1, Pages 82-86

Publisher

Elsevier BV

Online

2011-03-11

DOI

10.1016/j.urolonc.2010.09.018

Explore over 38,000 international journals covering a vast array of academic fields.

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started